Comparative Efficacy of Secukinumab Versus Tumor Necrosis Factor Inhibitors for the Treatment of Takayasu Arteritis

• Published in: Arthritis & rheumatology (Hoboken, N.J.) Vol. 75; no. 8; pp. 1415 - 1423
• Main Authors: Tian, Xinping, Li, Mengtao, Jiang, Nan, Zhao, Yang, Li, Jing, Zhou, Yangzhong, Wang, Yahong, Wang, Ying, Li, Taotao, Yang, Yunjiao, Wang, Yanhong, Merkel, Peter A., Zeng, Xiaofeng
• Format: Journal Article
• Language: English
• Published: Boston, USA Wiley Periodicals, Inc 01.08.2023; Wiley Subscription Services, Inc
• Subjects: Arteries; Arteritis; Cohort Studies; Effectiveness; Erythrocyte sedimentation rate; Glucocorticoids; Humans; Immunosuppressive agents; Immunosuppressive Agents - therapeutic use; Inhibitors; Interleukins; Monoclonal antibodies; Pathogenesis; Prospective Studies; Signs and symptoms; Takayasu Arteritis - drug therapy; Takayasu's disease; TNF inhibitors; Treatment Outcome; Tumor necrosis factor; Tumor Necrosis Factor Inhibitors - therapeutic use; Tumor Necrosis Factor-alpha; Tumor necrosis factor-TNF; Vein & artery diseases
• ISSN: 2326-5191; 2326-5205; 2326-5205
• DOI: 10.1002/art.42496

Objective Tumor necrosis factor (TNF) alpha and interleukin‐17 (IL‐17) are thought to be involved in the pathogenesis of Takayasu arteritis (TAK), and TNF inhibitors (TNFi) are recommended for the treatment of TAK. The present study was undertaken to investigate the efficacy of secukinumab, an IL‐17A monoclonal antibody, compared to treatment with TNFi. Methods This was a prospective, single‐center, open‐label cohort study. Patients with active TAK who did not respond to treatment with glucocorticoids combined with 2 immunosuppressive agents were treated with either secukinumab or TNFi as an add‐on therapy without an increased dosage of glucocorticoids. A complete response was defined as complete resolution of signs and symptoms of active disease, normal values of inflammatory markers, no progression on imaging of involved arteries, and dose of glucocorticoid <15 mg/day. A partial response was similarly defined as a complete response except with an erythrocyte sedimentation rate <40 mm/hour and C‐reactive protein level of <20 mg/liter. Results Nineteen patients in the secukinumab group and 34 patients in the TNFi group were enrolled. The demographic data and inflammatory markers of the 2 groups were comparable at baseline. Complete response and partial response for patients treated with secukinumab and TNFi were 31.6% and 58.8% (P = 0.057), respectively, at 3 months and 52.6% and 64.7%, respectively, at 6 months (P = 0.389). Conclusion Our findings suggest that secukinumab and TNFi are effective for patients with TAK who do not respond to oral glucocorticoids and conventional immunosuppressive agents, with similar response rates at 3 and 6 months.